Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Published:2022-03-05 Issue:6 Volume:24 Page:695-702
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Chen Yu-Wei,Rini Brian I.

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11912-022-01196-1.pdf

Reference39 articles.

1. Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

2. Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. CheckMate 214 demonstrated overall survival benefit of ipilimumab/nivolumab over sunitinib in advanced RCC.

3. Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. Keynote 426 demonstrated overall survival benefit of pembrolizumab/axitinib over sunitinib in advanced RCC.

4. Choueiri TK, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. CheckMate 9ER demonstrated overall survival benefit of nivolumab/cabozantinib over sunitinib in advanced RCC.

5. Motzer R, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. CLEAR trial demonstrated overall survival benefit of pembrolizumab/lenvatinib over sunitinib in advanced RCC.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Region of interest localization, tissue storage time, and antibody binding density—a technical note on the GeoMx® Digital Spatial Profiler;Immuno-Oncology and Technology;2024-09

2. Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”;Human Vaccines & Immunotherapeutics;2024-05-17

3. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations;Clinical & Experimental Metastasis;2024-02-16

4. External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations;2023-10-10

5. ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA);BMC Cancer;2023-08-09